Answers are grounded in this paper and cite their sources.
The asymmetric hydrogenation of a selectively crystallised (E)-4,4-diaryl-3-butenoate with a rhodium-PhanePhos catalyst is described, providing an intermediate to the antidepressant sertraline.
No takes yet. Share an insight, caveat, or question.
Boulton et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: